| Brian K Smith, MD | |
|
4401 Harrison Blvd, Ogden, UT 84403-3195 | |
| (801) 387-7615 | |
| (801) 387-7667 |
| Full Name | Brian K Smith |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 38 Years |
| Location | 4401 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780696641 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 176836-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Emergency Physicians | 1153307277 | 125 |
News Archive
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.
Patients whose mean arterial blood pressure drops during bypass surgery may be at risk for early difficulties in thinking, learning and memory, according to an article posted online today that will appear in the August 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
› Verified 3 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.
Patients whose mean arterial blood pressure drops during bypass surgery may be at risk for early difficulties in thinking, learning and memory, according to an article posted online today that will appear in the August 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
› Verified 3 days ago
| Entity Name | Utah Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588048979 PECOS PAC ID: 1153307277 Enrollment ID: O20040628001454 |
News Archive
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.
Patients whose mean arterial blood pressure drops during bypass surgery may be at risk for early difficulties in thinking, learning and memory, according to an article posted online today that will appear in the August 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian K Smith, MD 4401 Harrison Blvd, Ogden, UT 84403-3195 Ph: (801) 387-7615 | Brian K Smith, MD 4401 Harrison Blvd, Ogden, UT 84403-3195 Ph: (801) 387-7615 |
News Archive
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.
Patients whose mean arterial blood pressure drops during bypass surgery may be at risk for early difficulties in thinking, learning and memory, according to an article posted online today that will appear in the August 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
› Verified 3 days ago
Robert W Grow, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5475 Adams Ave Pkwy, Ogden, UT 84405 Phone: 801-479-2376 | |
Mrs. Ramsey Lee Gosselin, FNP Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5405 S 500 E Ste 100, Ogden, UT 84405 Phone: 801-475-7966 Fax: 801-475-7967 | |
Robert D Crofts, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-7615 Fax: 801-387-7667 | |
Spencer Page Ferrin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-7001 | |
Thomas E Garrison, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-7615 Fax: 801-387-7667 | |
Kristian Kemp, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5475 S 500 E, Ogden, UT 84405 Phone: 801-479-2111 | |
Mitchell Douglas Barneck, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-7000 |